The first stage (TOPARP-A) tested anti-tumor activity of olaparib in a sporadic mCRPC population [48]; the second stage (TOPARP-B) was conducted in patients with known genomic background, specifically BRCA2 or ATM mutations to assess sensitivity to olaparib [49]. Here, BRCA2 is linked to neoplasm.